A new study demonstrates that the combined usage of Aurora A kinase inhibitor (alisertib) and HSV1716 results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma.
A new study demonstrates that the combined usage of Aurora A kinase inhibitor (alisertib) and HSV1716 results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma.